Mabpharm (HKSE:02181) Debt-to-Equity : 1.27 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Mabpharm Debt-to-Equity?

Mabpharm's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$137.01 Mil. Mabpharm's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$147.46 Mil. Mabpharm's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$224.29 Mil. Mabpharm's debt to equity for the quarter that ended in Dec. 2023 was 1.27.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Mabpharm's Debt-to-Equity or its related term are showing as below:

HKSE:02181' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.32 Max: 1.27
Current: 1.27

During the past 7 years, the highest Debt-to-Equity Ratio of Mabpharm was 1.27. The lowest was 0.05. And the median was 0.32.

HKSE:02181's Debt-to-Equity is ranked worse than
90.34% of 1066 companies
in the Biotechnology industry
Industry Median: 0.145 vs HKSE:02181: 1.27

Mabpharm Debt-to-Equity Historical Data

The historical data trend for Mabpharm's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm Debt-to-Equity Chart

Mabpharm Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.10

0.05

0.08

0.32

1.27

Mabpharm Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial								0.08	0.26	0.32	0.48	1.27

Competitive Comparison of Mabpharm's Debt-to-Equity

For the Biotechnology subindustry, Mabpharm's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mabpharm's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabpharm's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Mabpharm's Debt-to-Equity falls into.

Mabpharm Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Mabpharm's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(137.005	+	147.458)	/	224.287
	=	1.27

Mabpharm's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(137.005	+	147.458)	/	224.287
	=	1.27

Mabpharm (HKSE:02181) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Mabpharm Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Mabpharm's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Mabpharm (HKSE:02181) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300

Website

http://www.mabpharm.cn

Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).

Executives

Guo Jianjun	2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines